Biopharma M&A: Mid-Cap Public-Target Market Survey (First-Half 2026)

In the first six months of 2026, acquirers announced 13 qualifying acquisitions of public biopharma targets worth $66.6 billion in upfront consideration. This survey examines that period and the surge within it: what is driving it, how the deals are structured, and what it means for the parties negotiating the next one. Focusing on the $1–25 billion public-target segment, the core of life-sciences M&A, it reads first-half 2026 against the preceding decade of dealmaking, going beyond deal count to track how consideration is paid, how often contingent value rights bridge valuation gaps, and the recent shift toward buyer-paid antitrust reverse termination fees to allocate closing risk.